Overview of lymphomas

Definition and types of lymphomas

Lymphoma is a malignancy affecting lymphocytes, which are white blood cells. The lymphatic system, a network of lymph nodes connected by vessels, is where they travel. When healthy lymphatic system cells undergo changes and grow out of control, lymphoma develops. A genetic mutation or other modification in the biology of immature lymphocytes causes them to proliferate quickly and form tumors in the lymph nodes or other regions of the body. Hodgkin Lymphoma and Non-Hodgkin Lymphoma are the two types of lymphoma.¹

Introduction to mantle cell lymphoma (MCL)

A subtype of non-Hodgkin lymphoma (NHL) is mantle cell lymphoma, named because of its beginning in B lymphocytes (B cells) situated in mantle zones of the lymph nodes. MCL is an uncommon blood cancer that begins in white blood cells in your lymph nodes. Before spreading more rapidly, this kind of cancer frequently develops slowly before the lymphatic system and other parts of your body are quickly invaded by mantle cell lymphoma.²

Causes and pathophysiology of MCL

It is unclear what specifically initiates MCL. As with various kinds of disease, numerous potential factors might add to its turn of events. These elements incorporate hereditary and immunologic anomalies, ecological variables, diet, stress, and others.

Many people with MCL have a particular, acquired genetic alteration involving a translocation at a specific area of chromosomes 11 and 14 (11q13 and 14q32). This specific translocation results in impaired functioning (i.e., dysregulation) of a gene (CCND1), which controls the synthesis of the protein cyclin D1. However, current research suggests that abnormalities in the family of proteins that regulate cell proliferation and the progression of the cell cycle include the cyclin D1 protein. As a result, malignant B-lymphocyte overgrowth and cell transformation likely result from cyclin D1 overexpression.

The harmful cells frequently express another gene, SOX11. B-cells do not typically contain SOX11; in any case, they very well might be found in the harmful B-cells of MCL. SOX11 is accepted to obstruct the separation of B cells with the goal that they stay in their basic state. Malignant cells give their strange changes to all their daughter cells and normally develop and partition at a quick, uncontrolled rate that is beyond the body’s natural immune defence. At last, such multiplication of strange cells might bring about the development of a mass known as a tumour.

Uncontrolled cellular growth and lymphocytic malignant transformation can cause the mantle zone, a lymph node's abnormal expansion, in MCL patients. Eventually, the region will be destroyed, and the boundaries of the mantle zone will be lost; and the potential for malignant lymphocytes to spread widely throughout the node.³

Symptoms of mantle cell lymphoma

Common symptoms

Painless swelling: The most typical symptom of MCL is painless swelling in the groin, armpit, or neck. 

B Symptoms

• Sweating profusely at night
• High temperatures (fevers)
• Unexplained weight loss

Other symptoms

• Loss of appetite
• Diarrhea
• Nausea
• A full feeling in the tummy-Weakness⁴

Comparison with other lymphomas

Clinical and molecular features of MCL and DLBCL

MCL and Diffuse large B cell lymphoma (DLBCL) are two unique kinds of lymphomas that can at times happen together in a condition called composite lymphoma. The NHL with the highest prevalence, DLBCL, accounts for approximately one-third of all cases. MCL is more uncommon and represents around four per cent of cases. DLBCL generally gives a forceful clinical course; around 60% of patients with advanced illnesses treated with R-CHOP achieve a cure. On the other hand, MCL is viewed as a moderately aggressive type of lymphoma, however, it is described as a typically incurable form of lymphoma that often progresses slowly.

The finding of MCL includes recognising the overexpression of cyclin D1 and the trademark chromosomal translocation, while DLBCL's conclusion depends on distinguishing huge B-cells positive for markers like CD20, CD10, and BCL6. Clinically, the two lymphomas can give easy lymph node expansion, spleen extension, and fundamental side effects like weakness, weight reduction, and night sweats. However, the aggressive nature of DLBCL frequently causes the symptom progression to be more rapid.⁵

Genetic susceptibility and cellular origin in CLL/SLL and MCL

Both mantle cell lymphoma (MCL) and chronic lymphocytic leukaemia (CLL)are B-cell lymphomas, although they differ greatly in terms of their features, course, and management. CLL is a neoplasm of mature B lymphocytes in the bone marrow and blood, prompting a gathering of little, mature lymphocytes. The development of CLL is significantly influenced by common genetic alterations, such as deletions in the 13q14 region and mutations in the TP53 and ATM genes. CLL generally advances gradually, with numerous patients staying asymptomatic for a long time. Similar to CLL, small lymphocytic lymphoma (SLL) primarily affects the spleen and lymph nodes rather than the blood or bone marrow. SLL and MCL can both cause lymph hub enlarging, yet SLL by and large advances all the more leisurely.

On the other hand, MCL is genetically characterised by the translocation t(11;14)(q13;q32) and CCND1 overexpression that is acquired in pre-B cells. Treatments for SLL are similar to those for CLL, focusing on targeted therapy and less aggressive chemotherapy compared to the more intensive regimens that are frequently required for MCL. MCL has increased genome insecurity contrasting to CLL, with countless underlying modifications per case. MCL will in general be more forceful than CLL, with fast sickness movement and a higher probability of including extranodal locales, like the gastrointestinal tract.⁶

Differential diagnosis

Both CLL/SLL and mantle cell lymphoma (MCL) have many characteristics in common and are caused by CD5+ B cells, their differentiation is basic as MCL is a more aggressive neoplasm. Under the magnifying lens, MCL cells show irregularly shaped nuclei and are more aggressive, while CLL/SLL cells have spherical, uniform cores, proposing a less forceful nature. All MCLs had a t(11;14) translocation and were CD5 positive and cyclin D1 positive. All CLL/SLL were CD5(+), CD23(+) and negative for cyclin D1 or t(11;14). The MCL and CLL/SLL components, according to IGH gene analysis, are likely derived from distinct neoplastic B-cells because their fragment sizes differ. The absence of a clonal connection between the MCL and CLL/SLL parts recommends that MCL and CLL/SLL are distinct diseases and don't share a common progenitor B-cell.⁷

Immunohistochemistry on pathology specimens is a fundamental part of separating MCL from other NHL, including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), small lymphocytic lymphoma/chronic lymphocytic leukaemia (SLL/CLL). SLL/CLL and DLBCL are primary differential diagnoses. Mantle cell lymphoma and SLL/CLL are both mature, CD5-positive B-cell lymphomas that may be difficult to distinguish using only flow cytometry. At the point when there is a positive for CD200 and CD23, the analysis is no doubt SLL/CLL. Mantle cell lymphoma is ordinarily negative for CD23 but positive for FMC7. FISH for t(11;14) or immunohistochemistry for cyclin D1 and/or SOX11 are typically used to confirm MCL. MCL is supported in tissue by consistent positive immunohistochemistry expression of B-cells by Cyclin D1 and SOX11. Cyclin D1 focal positive can occur in the SLL/CLL proliferation centres, but it shouldn't lead to an MCL diagnosis. When SOX11 and Cyclin D1 tests for big cell proliferation are negative, diffuse large B-cell lymphoma is considered.⁸

Treatment

• Monitoring: Before beginning the treatment, healthcare providers monitor the overall health and look for symptoms
• Chemotherapy: It is a common treatment for mantle cell lymphoma in the beginning.
• Therapy with monoclonal antibodies: Antibodies made in the lab are used in targeted therapy to locate and eradicate specific cancer cells
• Immunotherapy: By strengthening the immune system, this treatment combats cancer. Maintenance treatment: Long-term therapy, frequently involving monoclonal antibodies, helps stop cancer from returning after the first treatment
• Autologous stem cell transplantation: This rigorous course of treatment entails taking the patient's stem cells, giving them high-dose chemotherapy, and then reintroducing the stem cells into the body²

The stage of the disease, the size of the tumour, the symptoms, age, and overall health all play a role in the choice of treatment. At the time of finding, assuming that the ailment is in stage 1 or 2, patients may initially be treated with chemotherapy and immunotherapy induction, followed by combination radiation treatment to the impacted site. Assuming that the patient is in a further developed stage (stage 3 or 4), it is prescribed for them to get a rigorous treatment course with induction therapy followed via autologous undeveloped cell transplant and immunotherapy support.

Many of the medicines aimed at eliminating cancer cells may likewise harm solid cells, a large number of these treatments might be related to different secondary effects. As a result, patients ought to inquire of their doctors regarding the specific side effects that might be connected to particular treatments.³

FAQs

Is mantle cell lymphoma entirely curable?

No, some treatments can put the condition into remission.

How serious is mantle cell lymphoma?

Mantle cell lymphoma is a serious condition as it is an aggressive form of lymphoma and can spread quickly from the original lymph nodes to other lymph nodes, organs within the lymphatic system, or areas outside the lymphatic system.

Summary

It is essential to differentiate mantle cell lymphoma from different lymphomas as it might assist with diagnosis, treatment and prognosis. Our ability to accurately identify MCL due to advancements in diagnostic methods ensures that patients receive the most appropriate treatment for their particular lymphoma. When MCL is correctly identified, treatment options and the overall prognosis are affected, allowing healthcare providers to select the most effective treatment strategy for better disease management and outcomes.